The stock of Ideaya Biosciences Inc (IDYA) has gone down by -2.20% for the week, with a -7.15% drop in the past month and a -5.43% drop in the past quarter. The volatility ratio for the week is 4.89%, and the volatility levels for the past 30 days are 3.93% for IDYA. The simple moving average for the past 20 days is -4.91% for IDYA’s stock, with a 17.16% simple moving average for the past 200 days.
Is It Worth Investing in Ideaya Biosciences Inc (NASDAQ: IDYA) Right Now?
Company’s 36-month beta value is 0.83.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for IDYA is 65.96M, and currently, short sellers hold a 14.27% ratio of that floaft. The average trading volume of IDYA on April 24, 2024 was 704.87K shares.
IDYA) stock’s latest price update
Ideaya Biosciences Inc (NASDAQ: IDYA) has experienced a rise in its stock price by 0.68 compared to its previous closing price of 39.02. However, the company has seen a fall of -2.20% in its stock price over the last five trading days. Zacks Investment Research reported 2024-01-15 that IDEAYA Biosciences, Inc. (IDYA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Analysts’ Opinion of IDYA
Many brokerage firms have already submitted their reports for IDYA stocks, with BTIG Research repeating the rating for IDYA by listing it as a “Buy.” The predicted price for IDYA in the upcoming period, according to BTIG Research is $55 based on the research report published on March 08, 2024 of the current year 2024.
SVB Securities, on the other hand, stated in their research note that they expect to see IDYA reach a price target of $33. The rating they have provided for IDYA stocks is “Outperform” according to the report published on August 08th, 2023.
Goldman gave a rating of “Buy” to IDYA, setting the target price at $32 in the report published on May 24th of the previous year.
IDYA Trading at -9.85% from the 50-Day Moving Average
After a stumble in the market that brought IDYA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -17.70% of loss for the given period.
Volatility was left at 3.93%, however, over the last 30 days, the volatility rate increased by 4.89%, as shares sank -7.68% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -15.57% lower at present.
During the last 5 trading sessions, IDYA fell by -2.30%, which changed the moving average for the period of 200-days by +71.75% in comparison to the 20-day moving average, which settled at $41.15. In addition, Ideaya Biosciences Inc saw 10.42% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IDYA starting from Hata Yujiro S, who sale 23,557 shares at the price of $45.54 back on Feb 09 ’24. After this action, Hata Yujiro S now owns 677,887 shares of Ideaya Biosciences Inc, valued at $1,072,715 using the latest closing price.
Ruiz Briseno Andres sale 2,000 shares at $46.02 during a trade that took place back on Feb 09 ’24, which means that Ruiz Briseno Andres is holding 24,531 shares at $92,045 based on the most recent closing price.
Stock Fundamentals for IDYA
Current profitability levels for the company are sitting at:
- -5.75 for the present operating margin
- 0.83 for the gross margin
The net margin for Ideaya Biosciences Inc stands at -4.68. The total capital return value is set at -0.22. Equity return is now at value -23.28, with -21.78 for asset returns.
Based on Ideaya Biosciences Inc (IDYA), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -40.12. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is -6.26.
Currently, EBITDA for the company is -130.42 million with net debt to EBITDA at 1.16. When we switch over and look at the enterprise to sales, we see a ratio of 118.84. The receivables turnover for the company is 1299.17for trailing twelve months and the total asset turnover is 0.04. The liquidity ratio also appears to be rather interesting for investors as it stands at 19.65.
Conclusion
In a nutshell, Ideaya Biosciences Inc (IDYA) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
